Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | ATR | Q13535 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3662351 | 0.93 | AAK1 (0.46) | AAK1MAP4K4MCHR1JAK3ATM | |
| SCHEMBL2789586 | 0.87 | MAP4K4 (0.61) | MAP4K4CHRM4MCHR1 | |
| SCHEMBL1750255 | 0.87 | MAP4K4 (0.50) | AAK1MAP4K4CHRM4MCHR1 | |
| SCHEMBL528447 | 0.87 | MAP4K4 (0.50) | AAK1MAP4K4CHRM4MCHR1 | |
| SCHEMBL595852 | 0.87 | MAP4K4 (0.61) | MAP4K4CHRM4MCHR1 | |
| SCHEMBL1750039 | 0.81 | MAP4K4 (0.56) | MAP4K4MCHR1HRH3 | |
| SCHEMBL22165062 | 0.81 | MAP4K4 (0.56) | MAP4K4MCHR1HRH3 | |
| SCHEMBL529447 | 0.81 | MAP4K4 (0.56) | MAP4K4MCHR1HRH3 | |
| SCHEMBL2236554 | 0.81 | AAK1 (0.54) | AAK1MAP4K4CHRM4JAK3JAK1 | |
| SCHEMBL12265185 | 0.81 | AAK1 (0.54) | AAK1MAP4K4CHRM4JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155687-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | AAK1 813/4885MAP4K4 2328/4885CHRM4 4772/4885 |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | AAK1 813/4885MAP4K4 2328/4885CHRM4 4772/4885 |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | AAK1 813/4885MAP4K4 2328/4885CHRM4 4772/4885 |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | AAK1 813/4885MAP4K4 2328/4885CHRM4 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.